 |
Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. |
|
|
DNA Medicine Institute Affiliate Files for $1M Private Stock Offering
 |
NEW YORK (GenomeWeb News) – An affiliate of the DNA Medicine Institute plans to raise $1 million through a private stock offering, the Cambridge, Mass.-based firm disclosed in a document filed with the US Securities and Exchange Commission. |
|
Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer
 |
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing. "Despite the ... |
|
|
|
| MORE TOP STORIES |
|
| MORE DOMAINS |
|
|
